Built to Last: Taiwan’s Family-Owned Pharmas
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state subsidies in rival markets. "France’s industrial fabric risks being…
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through…
Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about leading the company’s pivot from a pure-play generics business into complex generics, biosimilars and new chemical entities. Anchored by its partnership with Formycon to launch a biosimilar to pembrolizumab, Patel…
The biggest opportunity is to dare more, invest in promising ideas and become better at translating our excellent science into successful businesses Germany has no shortage of scientific expertise, but…
I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated…
The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for…
America – once the undisputed global leader in medicine manufacturing – is today more reliant on pharma imports than at any time in its history. This dependence has steadily increased…
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort…
See our Cookie Privacy Policy Here
